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Abstract
Background: Chinese herbal products (CHPs) containing Radix bupleuri are often prescribed for chronic hepatitis. There
have been no epidemiological studies in populations with hepatitis B virus (HBV) infection. Our study was conducted to
determine the association between the use of CHPs containing Radix bupleuri and the risk of hospitalisation related to liver
injury among HBV-infected patients in Taiwan.
Methods: From a total of 639,779 patients with diagnoses related to HBV infection, we included hospitalised adult cases
with a primary diagnosis of liver injury in the database of Taiwan’s national health insurance during the period 1997–2004.
Case-control and case-crossover designs were used to assess the risk of hospitalisation with conditional logistic regression
models constructed and adjusted for 270 conventionally hepatotoxic drugs. Cumulative doses of these CHPs and Radix
bupleuri were assessed for any dose-response relationship.
Findings: In total, we collected 1,080 cases fulfilled the inclusion criteria. In the case-control design, the adjusted odds ratio
was 1.90 (95% confidence interval [CI]: 1.30 to 2.77). The risks from prescribing the CHPs Xiao-Chai-Hu-Tang and Long-Dan-
Xie-Gan-Tang were significantly high, and dose-response relationships were found. The risk of adding each 19 gm dose of
Radix bupleuri was 2.19 (95% CI: 1.66 to 2.89). The results using the case-crossover design remained similar.
Conclusions: Prescribing Xiao-Chai-Hu-Tang, Long-Dan-Xie-Gan-Tang, or CHPs containing more than 19 gram of Radix
bupleuri in HBV-infected patients might increase their risks of liver injury. Further studies are indicated to corroborate the
above findings.
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Introduction
An increasing number of herbal remedies are now being
reported as hepatotoxic, with such reports on Chinese herbal
products (CHPs) recently including a variety of types, such as Radix
scutellariae, Radix bupleuri,[1] Herba ephedrae,[2] Radix polygoni multi-
flori,[3] Atractylodis macrocephalae rhizoma, Radix glycyrrhizae,[4] Radix
paeoniae, Cortex moutan, and Cortex dictamni.[5,6] However, regular
users seem still to regard these remedies as ‘natural’ and
nontoxic.[7] CHPs are also prescribed for chronic hepatitis[8] in
Taiwan, especially in patients with hepatitis B virus (HBV)
infection.[9]
CHPs containing Radix bupleuri, such as Da-Chai-Hu-Tang
(Dai-saiko-to, TJ-8) and Xiao-Chai-Hu-Tang (syo-saiko-to, TJ-9)
have been reported to induce hepatotoxicity.[1,10,11,12] Among
them, Xiao-Chai-Hu-Tang is often prescribed to treat HBV
infection and the usual posology for Radix bupleuri is doses of 3–
9 g/day. [8,13,14] However, another study undertaken in Hong
Kong found that 32% of the patients with HBV infection had used
CHPs, and 9% of them experienced moderate to severe side
effects.[15]
Drug- or herb-induced liver injury is usually difficult to
detect.[16], [17] A post-market pharmacoepidemiologic survey
in a large automated database provides a method to detect the risk
associated with herbal medications. The National Health
Insurance (NHI) program in Taiwan is a universal system of
compulsory health insurance that has been providing coverage for
96.2% of the population of Taiwan since the end of 2000. The
Taiwanese government reimburses not only general healthcare
expenditures but also the costs of prescriptions for CHPs
(amounting to 780 different kinds of single herbs and mixed
formulae in concentrated extract form). [18] This computerised
database of CHPs provides us with an invaluable opportunity to
undertake a population-based study.
This study was conducted to determine the association between
the use of CHPs containing Radix bupleuri and the risk of




With strict confidentiality guidelines being closely followed in
accordance with personal electronic data protection regulations,
The National Health Research Institutes of Taiwan anonym zed
and maintained the NHI reimbursement data as files suitable for
research.[19] The identification numbers of all individuals with
reimbursement data in the NHI database were encrypted to
protect the privacy of the individuals. In addition, this study was
also approved by the Ethics Review Board at the National Taiwan
University College of Public Health.
NHI databases in Taiwan
The dataset for the study was obtained from the NHI Research
Database, which is a nationwide, population-based, reimburse-
ment database and all the personal identification has been
encrypted for research use.[20] The files are comprised of
comprehensive information on all medications prescribed to all
insured individuals. We conducted this study on both outpatient
visits and inpatient admission databases from January 1, 1997
through December 31, 2004.
Case selection
Cases included hospitalised patients who were older than 18
years of age and who suffered from liver injuries with diagnoses
related to HBV infection coded as 070.2, 070.3 and V02.61 by the
International Classification of Diseases, 9th Revision (ICD-9).[21]
Because liver diseases were the important health problems for our
country, the government pay more intention for this health issue
and make the guideline for diagnosis. [22] However, to prevent
any case misclassification, we only included incident cases with a
primary diagnosis of liver injury, and we excluded cases with other
diagnoses on admission or cases reported only from outpatient
clinics. Primary diagnoses of liver injury coded by the ICD-9
included acute and sub-acute necrosis of the liver (570), toxic
hepatitis (573.3), other specified disorders of liver (573.8), and
unspecified disorders of liver (573.9). Moreover, we excluded
patients who had been diagnosed with the following conditions at
any time before admission: viral hepatitis A, viral hepatitis C,
other viral hepatitis (070.0, 070.1, 070.4, 070.5, 070.6, 070.7, and
070.9), and viral hepatitis carriers (V02.60, V02.62, and V02.69);
cytomegalovirus and coxsackie virus diseases and infectious
mononucleosis (573.1 to 573.2); cholelithiasis (574.0 to 574.9);
alcoholic liver diseases, chronic hepatitis, cirrhosis of liver without
mention of alcohol, biliary cirrhosis, Other chronic nonalcoholic
liver disease, unspecified chronic liver disease without mention of
alcohol (571.0 to 571.9); abscess of the liver, portal pyemia, hepatic
coma, portal hypertension, hepatorenal syndrome, and chronic
passive congestion of the liver (572.0 to 573.0); malignant
neoplasm of liver and intrahepatic bile ducts (155.0 to 155.2),
liver metastasis (197.7), carcinoma in situ of the liver and biliary
system (230.8); and liver disorders during pregnancy (646.7).
Selection of referents in the case-control and case-
crossover designs
First, we analysed the datasets using a case-control design. Four
control subjects or referents for each case were randomly selected
by matching the age and gender from the same population with
HBV infection who did not have previous diagnoses of either liver
injury or any of the diseases that met the exclusion criteria for
cases. Namely, we first included all people with HBV-infected
diagnosis, excluded those with aforementioned diagnoses, and
then randomly drew 4 age- and gender- matched controls for each
case. In the case-crossover design, we set four referent exposure
windows before the recent exposure window and set 90 days
between them to prevent any carryover effect. We applied the 30-
day exposure windows in both designs.
CHPs containing Radix bupleuri and covariates
We selected all CHPs containing Radix bupleuri as our target
drugs. We then calculated the cumulative dose of CHPs prescribed
during each exposure window. Otherwise, we estimated the crude
dosage of Radix bupleuri in the CHPs in terms of both weight and
concentrated proportions, based on the concentrated mixed
products manufactured by different CHP companies and trans-
lated to the dose of crude herbs by concentrated ratio. Within a
commercial brand of Xiao-Chai-Hu-Tang, for example, the
registered weight proportion of Radix bupleuri was 0.33, whilst the
concentrated proportion was 4 and added the equal weight starch;
thus, a final product containing 1.0 gm of such a concentrated
CHP would be equivalent to 0.67 gm of Radix bupleuri in crude
form. The cumulative dosage of Radix bupleuri within the CHPs was
also calculated by adding together the total dosage prescribed
during each exposure windows. Then we stratified with the
median dose of the cumulative dosages to test for trends of dose-
response. Other hepatotoxic drugs and co-morbidities were
considered as covariates in the models. We undertook a search
of the MicromedexH database [23] for a total of 702 generic drugs
that had been previously reported as having any connection with
hepatotoxicity. The NHI in Taiwan regularly reimbursed for 270
of these generic drugs. We calculated the scores of Charlson
Comorbidity Index by using ICD-9 codes to determine the
condition of 1-year comorbidity.[24]
Data analysis
The use of CHPs containing Radix bupleuri by each case subject
during the exposure window was contrasted with the use of the
same CHPs for the same duration by the four matched control
subjects. The odds ratio (OR) was calculated for the exposure-odds
of case subjects and control subjects and denoted as a case-control
estimate. In the case-crossover design, the prevalence of CHPs
containing Radix bupleuri during the single recent exposure window
was contrasted with the prevalence over four reference windows
for the same case subject. Because the study designs included one
case matched with four controls or one recent exposure window
matched with four reference exposure windows, we analysed the
data through a conditional logistic regression model to explore the
association between hospitalisation and CHPs containing Radix
bupleuri. By adjusting two covariates in the case-control design (the
Charlson co-morbidity index scores and the frequency of the time-
variant hepatotoxic drugs during each exposure window) and by
adjusting the latter in the case-crossover design, we obtained the
adjusted ORs. The data analysis was performed and modelled to
calculate ORs and 95% CIs using SAS version 9.13 software (SAS
Institute Inc., Cary, NC).
Results
After conforming to the inclusion and exclusion criteria from
the population with 639,779 patients with HBV infection, the
sample was comprised of 1,080 cases with at least one 30-day
referent exposure window during the study period. Among them,
13.4% were 60 year of age or older, with a mean age of 40.2614.6
years. Table 1 shows that case subjects had larger Charlson co-
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drugs and CHPs per person than control subjects had.
In the case-control design, the adjusted OR during the 30-day
window was 1.90 (95% Confidence Interval (CI): 1.30 to 2.77)
between all products with Radix bupleuri and admissions with liver
injury. The risks from Xiao-Chai-Hu-Tang and Long-Dan-Xie-
Gan-Tang were significantly high, and the tests for trends in the
dose-response reaction were significant. The additional risk
incurred by adding each 19 gm dose of Radix bupleuri was 2.19
(CI: 1.66 to 2.89). The results using the case-crossover design
remained similar.
Discussion
Although our study found that the prescription of two CHPs
containing Radix bupleuri, Xiao-Chai-Hu-Tang and Long-Dan-
Xie-Gan-Tang, increased the risk of hospitalisation for liver injury
among HBV-infected subjects, it does not necessarily follow that
the association might be causal. We have following arguments to
suspect that the hypothesis is plausible.
The risk trends were consistent in both designs—case-control
and case crossover, and there seems a dose-response relationship,
as summarized in the Table 2. To prevent potential confounding
Table 1. Characteristics, co-morbidities, prescriptions and time-dependent hepatotoxic drugs for study subjects with viral
hepatitis B infection, 1997–2004.
Case Control
Characteristics Nos. % Nos. %
Total 1,080 100.0 4,320 100.0
Time independent covariates
Sex
Male 781 72.4 3124 72.4
Female 299 27.6 1196 27.6
Age
19–29 years 297 27.5 1188 27.5
29–39 years 292 27.1 1168 27.1
39–49 years 201 18.6 804 18.6
49–59 years 145 13.4 580 13.4
.=60 years 145 13.4 580 13.4
Admission diagnosis (ICD-9 code)
Acute and sub-acute liver necrosis (570) 792 73.3 0 0
Toxic hepatitis (573.3) 210 19.5 0 0
Other specified liver disorders (573.8) 65 6.0 0 0
Unspecified liver disorders (573.9) 13 1.2 0 0
Charlson co-morbidity index before admission
0 281 26.0 2756 63.8
1–2 639 59.2 1334 30.9
3–5 135 12.5 212 4.9
.5 25 2.3 18 0.4
Co-morbidities may enhance susceptibility to drug-induced liver injury No.
a % No.
a %
Diabetes mellitus 138 12.8 432 10.0
Obesity and hyperlipidemia 126 11.7 605 14.0
Neoplasms 94 8.7 729 16.9
Essential hypertension 85 7.9 501 11.6
Chronic kidney disease and renal failure 38 3.5 143 3.3
Hyperthyroidism 15 1.4 80 1.9
Systemic lupus erythematosus 7 0.6 10 0.2
Fasting, malnutrition 6 0.6 10 0.2
Pregnancy 0 0.0 45 1.0
Time dependent covariates
Prescriptions before admission No.
b per person No.
b per person
Chinese herbal products with Radix bupleuri 3,577 3.3 6,836 1.6
Hepatotoxic drugs 121,528 112.5 350,605 81.2
ICD-9, International Classification of Diseases, 9th Revision.
aEach subject could have more than one co-morbidity before admission.
bEach subject could have more than one prescription and co-prescription.
doi:10.1371/journal.pone.0016064.t001
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hospitalised and excluded other possible causes of hepatobiliary
diseases, including all other hepatitis-related infections, alcohol-
related liver disorders, cholelithiasis and de-compensated hepatic
conditions, as these conditions might make patients more likely to
suffer liver injury from exposure to potentially hepatotoxic drugs.
Our estimates were more conservative as we did not include the
above cases. Because we did not have any direct access to the
original clinical data, our study was necessarily limited to the more
severe cases resulting in hospitalisations, which may increase the
validity of the diagnosis but undoubtedly resulted in an
underestimation of hepatotoxicity with only mild manifestations.
Another potential explanation is the confounding by indication,
as the two major CHPs were frequently prescribed by Chinese
medicine doctors to treat hepatitis. However, the most frequently
prescribed CHP containing Radix bupleuri for subjects with HBV
infection was Jia-Wei-Xia-Yao-San and the adjusted OR was 1.87
(CI: 0.69 to 5.06) by case-crossover design (Table 2). Moreover,
prescriptions of all the other CHPs containing Radix bupleuri
combined together did not show a significantly higher risk of liver
injury, either. As these products were usually prescribed to HBV-
infected patients, or, supposedly to be associated with HBV
infection, the results of no existing association in other CHPs
might serve as a contrast against the possibility of confounding by
indication. However, since the number for each individual CHPs
is small, we cannot draw a strong inference.
To test the potential dose-response relationship, we summed up
the cumulative prescribed doses of Radix bupleuri for every window
period of each patient, and then stratified the groups into 0, below
and above the median dose of 19 gm. We detected a statistically
significant linear trend between the increased dose and hospital-
ization related to liver injury (Table 2). We conducted further
sensitivity analyses by stratification to clarify the misclassifications
and potential confounders in the case-crossover design. The results
reveal no significant changes in the ORs of the subgroups stratified
by different prescribing conditions, matched patterns and co-
morbidities.[16] Although the medications being studied were co-
prescribed with seven potentially hepatotoxic drugs, the results
reveal no significant contributions of drug-drug interactions.
(Appendix S1) Since there is no other alternative explanation for
the reasons of hospitalisation, we tentatively conclude that the
association between liver injury and CHPs containing Radix
bupleuri in HBV-infected patients exists and deserves our attention.
In Japan, Xiao-Chai-Hu-Tang and other CHPs containing
Radix bupleuri produced no significant effect of acute and chronic
toxicity on rats.[25] However, these animals were not suffering
Table 2. Number of exposed subjects with viral hepatitis B in the 30-day windows and adjusted odds ratios between
hospitalisations with liver injury and Chinese herbal products with Radix bupleuri by case-control and case-crossover designs,
1997–2004.












a 95% C.I. OR
b 95% C.I.
Total no. 1,080 4,320 4,320
All products
c with Radix bupleuri 61 89 1.90 1.30 2.77 155 1.75 1.22 2.50
Xiao-Chai-Hu-Tang 19 23 2.91 1.36 6.24 26 2.81 1.36 5.78
Cumulative dose .=31gm
d 8 11 1.92 0.69 5.36 15 1.63 0.60 4.45
Cumulative dose ,31 gm 11 12 3.08 1.18 8.09 11 3.43 1.37 8.59
Test of linear trend for 0, ,31, .=31 gm 1.77 1.09 2.88 1.67 1.06 2.65
Long-Dan-Xie-Gan-Tang 14 20 3.52 1.56 7.95 29 2.31 1.11 4.80
Cumulative dose .=36gm
d 8 6 5.14 1.62 16.33 14 2.72 1.01 7.29
Cumulative dose ,36 gm 6 14 2.03 0.64 6.44 15 1.69 0.61 4.63
Test of linear trend for 0, ,36, .=36 gm 2.34 1.37 3.99 1.72 1.09 2.73
Jia-Wei-Xia-Yao-San 7 25 2.07 0.72 5.92 26 1.87 0.69 5.06
All other CHPs combined
e 36 108 1.42 0.85 2.37 120 1.19 0.76 1.85
Content of Radix bupleuri in all CHPs
c
Cumulative dose .=19gm
d 28 67 5.17 2.79 9.56 81 1.91 1.19 3.06
Cumulative dose ,19 gm 33 22 1.40 0.83 2.35 26 1.36 0.85 2.19
Test of linear trend for 0, ,19, .=19 gm 2.19 1.66 2.89 1.44 1.15 1.80
no., number; OR, odds ratio; CI, confidence interval.
aAdjusted for the frequency of the time-variant hepatotoxic drugs during every exposure window and the scores of the Charlson co-morbidity index score for one year
prior to admission.
bAdjusted for the frequency of the time-variant hepatotoxic drugs during every exposure window.
cCHPs with Radix bupleuri prescribed by cases and controls or in recent and reference windows: Jia-Wei-Xia-Yao-San, Long-Dan-Xie-Gan-Tang, Xiao-Chai-Hu-Tang (Sho-
Saiko-To, TJ-9), Chai-Hu-Qing-Gan-Tang, Chai-Hu-Su-Gan-Tang, Jing-Fang-Bai-Du-San, Hsieh-Fu-Chu-Yu-Tang, Chai-Ge-Jie-Ji-Tang, Bu-Zhong-Yi-Qi-Tang, Chai-Hu-Gei-
Zhi-Tang, Xia-Yao-San, Zi-Shen-Tong-Er-Tang, Pu-Ji-Xiao-Du-Yin, Qin-Jiao-Bie-Jia-San, Yi- Gan-San, Si-Ni-San, Da-Chai-Hu-Tang, Chai-Hu-Jia-Long-Gu-mu-Li-Tang, Chai-
Hu-Xian-Xiong-Tang, Qing-Kong-Gao, San-Zhong-Kui-Jian-Tang, Jing-Jie-Lian-Qiao-Tang, Wan-Dai-Tang, Shen-Mi-Tang, Ren-Shen-Bai-Du-San, Sheng-Yang-Yi-Wei-Tang,
Fu-Yuan-Huo-Xue-Tang, Dun-Sou-Tang, and Chai-Hu.
dThe cut-off points for categories were the medians of all cumulative doses.
eCumulative doses cannot be classified due to different CHPs.
doi:10.1371/journal.pone.0016064.t002
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HBV-infected cases with liver injury, Yuen et al. found 45 cases
with suspected CHP-associated liver injury. [26] A hospital-based
questionnaire survey found 10 of 116 patients who had taken
CHPs experienced side effects.[15] But they did not explore the
detailed active ingredients in the exposed CHPs. The only one
clinical trial that involved applying Xiao-Chai-Hu-Tang in 16
HBV-infected patients with cirrhosis for 60 months (or, a total of
80 person years) did not detect any side effect.[27] Our study is
conducted on a nation-wide basis and followed for 7 years, of
which we collected 281,982 person-years of exposure to Xiao-
Chai-Hu-Tang and there were a total of 224 cases with liver injury
that required hospitalisation, which reveals an annual incidence
rate of 7.94610
24 per year, while that of Long-Dan-Xie-Gan-
Tang is 5.96610
24.
Potential limitations of this study, including unmeasured
confounders, use of other out-of-pocket drugs, and patient
compliance should also be discussed. First, the NHI reimburses
for prescribed CHPs in concentrated extract form only, whereas
herbal stores can sell raw herbs for patients to self-prepare
decoction, according to the Pharmaceutical Affairs Law in
Taiwan. The potential impact of current practices should not be
ignored. However, as self-purchased raw herbs were not regularly
reimbursed, people usually take them once in a while or when the
CHPs fails to improve the symptom. Thus, the cumulative dose is
usually small after stratification for different window periods.
Furthermore, if such habits among patients remained unchanged
within a 2-year period, the case-crossover design might eliminate
this potential confounding, taking the advantage of each patient
serving as his/her own control. Finally, this study also presumed
that all prescribed medications were actually taken by subjects as
prescribed, which may overestimate the actual ingested dosage, as
some degree of noncompliance is always expected.
Conclusions
Our study found that HBV-infected subjects using Xiao-Chai-
Hu-Tang and Long-Dan-Xie-Gan-Tang had an increased risk of
liver injury, and there was a statistically significant linear trend of
dose-response for the cumulative prescribed doses of Radix bupleuri.
Thus, we recommend that physicians should carefully monitor
hepatic function in the subjects who are taking these CHPs
regularly. Moreover, if liver injury occurs, Xiao-Chai-Hu-Tang
and Long-Dan-Xie-Gan-Tang should be considered as the
potential sources of hepatotoxicity. However, further mechanistic
research on the hepatotoxicity of Radix bupleuri in the presence of
HBV infection is warranted.
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